Publication | Closed Access

Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)

Docetaxel ChemotherapyIfct-0301 StudyMedicineMetronomic TherapyClinical TrialsBronchial NeoplasmPerformance StatusPharmacotherapyCancer TreatmentOncologyRadiation OncologyLung CancerMolecular OncologyHealth Sciences